Sirna Therapeutics expects to yield a clinical candidate for its Huntington’s disease program before the end of the year, after company researchers were able to achieve significant knockdown of the disease-causing gene resulting in improved motor function in a mouse model using a vector-expressed siRNA, according to CEO and President Howard Robin.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.